Uterine serous carcinoma.
Endometrial cancer
Immunotherapy
Serous uterine cancer
Targeted therapy
Journal
Gynecologic oncology
ISSN: 1095-6859
Titre abrégé: Gynecol Oncol
Pays: United States
ID NLM: 0365304
Informations de publication
Date de publication:
07 2021
07 2021
Historique:
received:
19
03
2021
accepted:
23
04
2021
pubmed:
4
5
2021
medline:
31
12
2021
entrez:
3
5
2021
Statut:
ppublish
Résumé
Serous endometrial cancer represents a relative rare entity accounting for about 10% of all diagnosed endometrial cancer, but it is responsible for 40% of endometrial cancer-related deaths. Patients with serous endometrial cancer are often diagnosed at earlier disease stage, but remain at higher risk of recurrence and poorer prognosis when compared stage-for-stage with endometrioid subtype endometrial cancer. Serous endometrial cancers are characterized by marked nuclear atypia and abnormal p53 staining in immunohistochemistry. The mainstay of treatment for newly diagnosed serous endometrial cancer includes a multi-modal therapy with surgery, chemotherapy and/or radiotherapy. Unfortunately, despite these efforts, survival outcomes still remain poor. Recently, The Cancer Genome Atlas (TCGA) Research Network classified all endometrial cancer types into four categories, of which, serous endometrial cancer mostly is found within the "copy number high" group. This group is characterized by the increased cell cycle deregulation (e.g., CCNE1, MYC, PPP2R1A, PIKCA, ERBB2 and CDKN2A) and TP53 mutations (90%). To date, the combination of pembrolizumab and lenvatinib is an effective treatment modality in second-line therapy, with a response rate of 50% in advanced/recurrent serous endometrial cancer. Owing to the unfavorable outcomes of serous endometrial cancer, clinical trials are a priority. At present, ongoing studies are testing novel combinations of various targeted and immunotherapeutic agents in newly diagnosed and advanced/recurrent endometrial cancer - an important strategy for serous endometrial cancer, whereby tumors are usually p53+ and pMMR, making response to PD-1 inhibitor monotherapy unlikely. Here, the rare tumor working group (including members from the European Society of Gynecologic Oncology (ESGO), Gynecologic Cancer Intergroup (GCIG), and Japanese Gynecologic Oncology Group (JGOG)), performed a narrative review reporting on the current landscape of serous endometrial cancer and focusing on standard and emerging therapeutic options for patients affected by this difficult disease.
Identifiants
pubmed: 33934848
pii: S0090-8258(21)00349-8
doi: 10.1016/j.ygyno.2021.04.029
pmc: PMC9445918
mid: NIHMS1827604
pii:
doi:
Types de publication
Journal Article
Review
Langues
eng
Sous-ensembles de citation
IM
Pagination
226-234Subventions
Organisme : NCI NIH HHS
ID : P30 CA008748
Pays : United States
Organisme : NCI NIH HHS
ID : P30 CA016042
Pays : United States
Informations de copyright
Copyright © 2021. Published by Elsevier Inc.
Références
J Clin Oncol. 2012 Mar 1;30(7):695-700
pubmed: 22291074
Cancer Control. 2009 Jan;16(1):46-52
pubmed: 19078929
Gynecol Oncol. 2020 Dec;159(3):732-736
pubmed: 33004215
CA Cancer J Clin. 2020 Jan;70(1):7-30
pubmed: 31912902
Gynecol Oncol. 2018 May;149(2):283-290
pubmed: 29544706
J Clin Oncol. 2018 Jul 10;36(20):2044-2051
pubmed: 29584549
Eur J Cancer. 2010 Sep;46(13):2422-31
pubmed: 20619634
CA Cancer J Clin. 2010 Sep-Oct;60(5):277-300
pubmed: 20610543
Lancet Oncol. 2017 Mar;18(3):384-392
pubmed: 28159465
Cancer. 2021 Feb 15;127(4):598-608
pubmed: 33151547
N Engl J Med. 2020 Nov 19;383(21):2053-2064
pubmed: 33207095
Oncoscience. 2020 Jun 8;7(9-10):68-69
pubmed: 33195736
Gynecol Oncol. 2019 Dec;155(3):429-435
pubmed: 31610885
Gynecol Obstet Invest. 2018;83(5):482-486
pubmed: 28848103
Lancet Oncol. 2019 Sep;20(9):1273-1285
pubmed: 31345626
Eur J Cancer. 2019 Jul;116:77-85
pubmed: 31181536
JAMA Surg. 2021 Feb 1;156(2):157-164
pubmed: 33175109
Lancet. 2010 Apr 3;375(9721):1165-72
pubmed: 20188410
Proc Natl Acad Sci U S A. 2013 Feb 19;110(8):2916-21
pubmed: 23359684
Lancet Oncol. 2019 Aug;20(8):1124-1135
pubmed: 31257177
Gynecol Oncol. 2017 Aug;146(2):234-239
pubmed: 28528918
Hum Pathol. 1995 Nov;26(11):1260-7
pubmed: 7590702
Gynecol Oncol. 2019 Jun;153(3):676-683
pubmed: 30952370
Cancer Manag Res. 2018 Oct 25;10:4915-4928
pubmed: 30464593
J Clin Oncol. 2020 Sep 10;38(26):2981-2992
pubmed: 32167863
Gynecol Oncol. 2004 Dec;95(3):593-6
pubmed: 15581969
Gynecol Oncol. 2021 Apr;161(1):122-129
pubmed: 33485641
Int J Gynecol Cancer. 2021 Jan;31(1):12-39
pubmed: 33397713
Oncol Res Treat. 2019;42(9):466-469
pubmed: 31340208
Lancet Oncol. 2019 May;20(5):711-718
pubmed: 30922731
Clin Cancer Res. 2020 Oct 1;26(19):5062-5067
pubmed: 32295834
Int J Gynecol Pathol. 2019 Jan;38 Suppl 1:S64-S74
pubmed: 30550484
J Contemp Brachytherapy. 2020 Feb;12(1):61-66
pubmed: 32190072
Gynecol Oncol. 2020 Dec;159(3):721-731
pubmed: 32988624
Br J Cancer. 2010 Jan 5;102(1):134-43
pubmed: 19920829
Gynecol Oncol Rep. 2020 Jan 02;31:100532
pubmed: 31934607
Crit Rev Oncol Hematol. 2020 Aug;152:102973
pubmed: 32497971
Clin Cancer Res. 2020 Aug 1;26(15):3928-3935
pubmed: 32601075
Int J Gynecol Cancer. 2020 Aug;30(8):1089-1094
pubmed: 32675056
Reprod Sci. 2013 Apr;20(4):449-55
pubmed: 22995987
Clin Cancer Res. 2020 May 15;26(10):2393-2403
pubmed: 32034078
Expert Rev Anticancer Ther. 2012 Jan;12(1):41-9
pubmed: 22149431
Gynecol Oncol Rep. 2020 Feb 25;32:100554
pubmed: 32140533
JAMA Netw Open. 2020 Dec 1;3(12):e2028612
pubmed: 33295973
Nature. 2013 May 2;497(7447):67-73
pubmed: 23636398
Clin Cancer Res. 2021 Jan 1;27(1):43-51
pubmed: 33109737
Gynecol Oncol. 2017 Jul;146(1):3-10
pubmed: 28372871
Mol Cancer Ther. 2015 Nov;14(11):2519-26
pubmed: 26333383
J Natl Compr Canc Netw. 2018 Feb;16(2):170-199
pubmed: 29439178
N Engl J Med. 2019 Jun 13;380(24):2317-2326
pubmed: 31189035
Cancer Res. 2012 Aug 15;72(16):4060-73
pubmed: 22896685
Tumori. 2019 Feb;105(1):92-97
pubmed: 29984612
Gynecol Oncol. 2019 Apr;153(1):158-164
pubmed: 30630630
Mol Cancer Ther. 2017 Nov;16(11):2609-2617
pubmed: 28751540
Gynecol Oncol. 2019 Oct;155(1):13-20
pubmed: 31395371